The National Institutes of Health (NIH) recently said it will fund clinical trials to exam the safety and efficacy of psychedelic-assisted therapy in older adults with chronic pain, reported Marijuana Moment.
According to NIH's Wednesday notice, it intends to direct $8.4 million toward research on "classic" psychedelics such as psilocybin, N, N-Dimethyltryptamine (DMT), lysergic acid diethylamide (LSD) and mescaline, as well as methylenedioxymethamphetamine (MDMA).
The funding notice pointed out that roughly 40% of older Americans said they've been living with chronic pain caused by musculoskeletal conditions, neuropathies and cancer.
Interestingly the document highlighted that cannabis and ketamine are not "considered psychedelic agents" for the purpose.
The new approach seeks to provide an alternative to mainstream treatments, which researchers called "complex and often inadequate."
Why It Matters
Traditional treatment often includes acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opioids and atypical analgesics with "limited efficacy," and come with a risk of adverse effects in older adults.
Meanwhile, "analgesics and non-pharmacologic therapies like cognitive behavioral therapy, physical activity regimens, acupuncture, and electrical stimulation" often have "variable efficacy and uptake," the researchers explained.
Enter psychedelic-assisted therapy (PAT).
"PAT uses psychedelic agents in combination with psychological support or psychotherapy in a conducive environment ("set and setting")," said the funding notice.”Evidence for the efficacy of PAT has been particularly notable in depression, anxiety (especially existential distress), post-traumatic stress disorder (PTSD), and substance use disorders, among other indications."
What's Next?
The grant will be supervised by the National Institute on Aging (NIA) and the National Center for Complementary and Integrative Health (NCCIH). It will award up to $3.4 million annually in fiscal 2025–2026 and up to $5 million per year in fiscal 2027–2029.
Who Can Apply
Eligible organizations that can apply for the grant include higher education institutions, nonprofits, local governments and federal agencies and for-profit organizations, to name a few. Foreign organizations are not eligible to apply.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!